In the BioHarmony Drug Report Database

"Preview" Icon

Lumasiran

Oxlumo (lumasiran) is an oligonucleotide pharmaceutical. Lumasiran was first approved as Oxlumo on 2020-11-19. It has been approved in Europe to treat primary hyperoxaluria. Oxlumo’s patents are valid until 2035-10-09 (FDA).

 

Trade Name

 

Oxlumo
 

Common Name

 

lumasiran
 

ChEMBL ID

 

CHEMBL4297779
 

Indication

 

primary hyperoxaluria
 

Drug Class

 

Image (chem structure or protein)

Lumasiran structure rendering